Top Markets
#1 Helium Helium +94.28%
#2 MowCat MowCat +80.93%
#3 Seeker Seeker +59.15%
#4 UnifAI Network UnifAI Network +34.35%
#5 Tensor Tensor +31.21%
#6 TENDIES TENDIES +26.57%
#7 AI XOVIA AI XOVIA +24.77%
#8 Pons Pons +24.26%
#9 Zylo Ecosystem Zylo Ecosystem +21.75%
#10 Bounce Bounce +18.99%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Ergomed plc Ergomed plc

Ergomed plc

2EM
Rank in Stocks #11481
Ergomed plc, alongside its affiliated entities, offers a comprehensive range of... Ergomed plc, alongside its affiliated entities, offers a comprehensive range of clinical trial services, encompassing planning, oversight, and execution, in addition to providing essential drug safety and medical information support. The company maintains an expansive global footprint, conducting operations throughout the United Kingdom, continental Europe, the Middle East, Africa, North America, Asia, and Australia. Its business is organized into two core divisions: Clinical Research Services and Pharmacovigilance. Ergomed assists pharmaceutical, biotechnology, and generic drug manufacturers by managing clinical development programs, facilitating post-market approval strategies, and delivering robust pharmacovigilance solutions. Their expertise is concentrated in several therapeutic domains, including oncology, haematology, allergy, respiratory, and neurology/CNS, with a notable specialization in the development of orphan drugs. Furthermore, they extend support services to clinical trial sites. Established in 1997, the organization originally traded as Ergomed Clinical Research Limited before rebranding as Ergomed plc in June 2014. Its corporate headquarters are situated in Guildford, United Kingdom.
Share Price
$13.05
Last synced: 2023-03-31
Market Cap
$695.07M
Change (1 day)
4.59%
Change (1 year)
0.00%
Country
GB
Trade Ergomed plc (2EM)

Category

Healthcare
P/E ratio for Ergomed plc (2EM)
P/E ratio as of 2026 TTM: 0
According to Ergomed plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Ergomed plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.